Investor Presentaiton

Investor presentation Full year 2018 Slide 82 In the completed PIONEER trials between 52-80% of patients on oral semaglutide achieved an HbA1c level <7% In completed PIONEER trials 52-80% of patients achieved an HbA1c level <7.0% (ADA guidance)¹ Proportion of patients In completed PIONEER trials 28-49% of patients achieved a weight loss of ≥ 5%¹ Proportion of patients (%) (%) 100% 100% 80%* 80%* 80% 72%* 75%* 80% 69%* 64%*63%*64%* 60% 52%* 60% 44%* 47% 49%* 49%* * 41%* 40% 40% 20% 20% تتاتتاتلر 25%* 0% 0% P1 P2 P3 P4 P5 P7 P8 P9 P10 P1 P2 P3 P4 P5 P7 P8 P9 P10 1 Hypothetical estimand, observed data * Statistically significant vs comparator (PIONEER 1 vs placebo; PIONEER 2 vs empagliflozin 25 mg; PIONEER 3 vs sitagliptin 100 mg; PIONEER 4 vs Victoza® 1.8 mg; PIONEER 5 vs. placebo in T2DM and with renal impairment; PIONEER 7 vs sitagliptin 100 mg; PIONEER 10 vs. dulaglutide in Japanese people) Note: Results shown are: PIONEER 1 for 26 weeks with 14 mg oral semaglutide; PIONEER 2, 4 and 9 for 52 weeks with 14 mg oral semaglutide; PIONEER 3 for 78 weeks with 14 mg oral semaglutide; PIONEER 7 for 52 weeks with a mixed dose. PIONEER 6 not included as it was a CVOT. T2DM: Type 2 diabetes mellitus; CVOT: Cardiovascular outcomes trial; ADA: American Diabetes Association Source: Novo Nordisk data on file

View entire presentation